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BACKGROUND
Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor sub-
types 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing 
the number of activated lymphocytes circulating to the gastrointestinal tract.
METHODS
We conducted a double-blind, placebo-controlled phase 2 trial of ozanimod in 197 
adults with moderate-to-severe ulcerative colitis. Patients were randomly assigned, in 
a 1:1:1 ratio, to receive ozanimod at a dose of 0.5 mg or 1 mg or placebo daily for up 
to 32 weeks. The Mayo Clinic score was used to measure disease activity on a scale 
from 0 to 12, with higher scores indicating more severe disease; subscores range from 
0 to 3, with higher scores indicating more severe disease. The primary outcome was 
clinical remission (Mayo Clinic score ≤2, with no subscore >1) at 8 weeks.
RESULTS
The primary outcome occurred in 16% of the patients who received 1 mg of ozanimod 
and in 14% of those who received 0.5 mg of ozanimod, as compared with 6% of those 
who received placebo (P = 0.048 and P = 0.14, respectively, for the comparison of the 
two doses of ozanimod with placebo). Differences in the primary outcome between 
the group that received 0.5 mg of ozanimod and the placebo group were not significant; 
therefore, the hierarchical testing plan deemed the analyses of secondary outcomes 
exploratory. Clinical response (decrease in Mayo Clinic score of ≥3 points and ≥30% 
and decrease in rectal-bleeding subscore of ≥1 point or a subscore ≤1) at 8 weeks oc-
curred in 57% of those receiving 1 mg of ozanimod and 54% of those receiving 0.5 mg, 
as compared with 37% of those receiving placebo. At week 32, the rate of clinical re-
mission was 21% in the group that received 1 mg of ozanimod, 26% in the group that 
received 0.5 mg of ozanimod, and 6% in the group that received placebo; the rate of 
clinical response was 51%, 35%, and 20%, respectively. At week 8, absolute lympho-
cyte counts declined 49% from baseline in the group that received 1 mg of ozanimod 
and 32% from baseline in the group that received 0.5 mg. The most common adverse 
events overall were anemia and headache.
CONCLUSIONS
In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a slightly higher 
rate of clinical remission of ulcerative colitis than placebo. The trial was not large 
enough or of sufficiently long duration to establish clinical efficacy or assess safety. 
(Funded by Receptos; TOUCHSTONE ClinicalTrials.gov number, NCT01647516.)
A BS TR AC T
Ozanimod Induction and Maintenance 
Treatment for Ulcerative Colitis
William J. Sandborn, M.D., Brian G. Feagan, M.D., Douglas C. Wolf, M.D., 
Geert D’Haens, M.D., Ph.D., Severine Vermeire, M.D., Ph.D., 
Stephen B. Hanauer, M.D., Subrata Ghosh, M.D., Heather Smith, M.B.A., 
Matthew Cravets, M.A., Paul A. Frohna, M.D., Ph.D., Richard Aranda, M.D., 
Sheila Gujrathi, M.D., and Allan Olson, M.D.,  
for the TOUCHSTONE Study Group* 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF BIRMINGHAM on May 9, 2017. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
n engl j med 374;18 nejm.org May 5, 2016 1755
Ozanimod Treatment for Ulcer ative Colitis
Ulcerative colitis is a chronic  immune-mediated disease of the colon that is currently treated with mesala-
mine, glucocorticoids, thiopurines, and biologic 
agents.1,2 A lack of universal response, the risks 
of infection and neoplasia, a requirement for 
parenteral administration, and the development 
of antidrug antibodies have created a need for 
safe and effective oral therapies.
The sphingosine-1-phosphate (S1P) subtype 1 
(S1P1) receptor is a member of a family of five 
widely expressed receptors (S1P1 through S1P5) 
that are responsible for regulating multiple im-
munologic and cardiovascular effects.3,4 Cell-
surface–associated S1P1 receptor plays a crucial 
role in the trafficking of lymphocytes from 
lymphoid organs.5,6 S1P1-receptor agonists in-
duce internalization and degradation of the S1P1 
receptor, rendering B and T lymphocytes inca-
pable of migrating from secondary lymphoid 
organs, which leads to a reversible reduction in 
circulating lymphocytes in the blood.4,5,7
Patients treated with fingolimod (Gilenya, 
Novartis), a S1P-receptor modulator that has 
been approved for the treatment of relapsing 
multiple sclerosis,8,9 have a decrease from base-
line of 70 to 80% in the peripheral-blood lym-
phocyte count owing to lymph-node sequestra-
tion of naive and central memory lymphocytes. 
In contrast, the number of effector memory 
T cells remains comparatively unchanged, which 
probably preserves immunosurveillance.10,11 How-
ever, rare cases of serious disseminated varicella–
zoster and herpes simplex infections have been 
reported.12 Fingolimod is not selective for the 
S1P1 receptor and binds to an additional three 
of the five receptor subtypes (S1P3, S1P4, and 
S1P5), which may lead to adverse events, includ-
ing cardiovascular effects such as bradycardia 
(in <1% of patients), second-degree atrioventric-
ular blocks (in 4%), elevation of liver amino-
transferase levels (in 14%), and macular edema 
(in <1%).13-15
Ozanimod (RPC1063) is a new oral S1P1- 
receptor and S1P5-receptor modulator with no 
activity on S1P2, S1P3, and S1P4.16 A phase 2 
trial of ozanimod in patients with relapsing 
multiple sclerosis showed a dose-dependent re-
duction in circulating lymphocytes that was as-
sociated with significant reductions in inflamma-
tory and neurodegenerative brain lesions, with 
minimal effects on heart rate and liver en-
zymes.17 We evaluated the efficacy and safety of 
ozanimod in patients with moderately to severely 
active ulcerative colitis.
Me thods
Trial Oversight
From December 2012 through April 2015, we 
conducted this randomized, double-blind, placebo-
controlled phase 2 trial of induction and main-
tenance therapy at 57 centers in 13 countries. 
The protocol, available with the full text of this 
article at NEJM.org, was approved by the institu-
tional review board at each center. All the pa-
tients provided written informed consent.
The members of the steering committee (see 
the Supplementary Appendix, available at NEJM 
.org) designed the trial in collaboration with the 
sponsor (Receptos). Data were collected by a 
contract research organization (Pharmaceutical 
Product Development) and analyzed by the spon-
sor. The sponsor and the steering committee 
interpreted the data jointly. All the authors had 
full access to the data. The first two authors 
wrote the first draft of the manuscript, and all 
the authors contributed to subsequent drafts, 
made a collective decision to submit the manu-
script for publication, and vouch for the com-
pleteness and veracity of the data and analyses 
reported and for the adherence of the trial to the 
protocol. Editorial support was provided by the 
sponsor and by Robarts Clinical Trials (funded 
by the sponsor). Confidentiality agreements were 
in place between the sponsor and all the authors.
Patients
Eligible patients were 18 to 75 years of age and 
had ulcerative colitis, with a Mayo Clinic score18 
of 6 to 12 and an endoscopic subscore of 2 or 3, 
as determined by blinded central read. The Mayo 
Clinic score was used to measure disease activ-
ity on a scale from 0 to 12, with higher values 
indicating more severe disease18; subscores range 
from 0 to 3, with higher scores indicating more 
severe disease. Treatment with oral amino-
salicylates or prednisone (≤30 mg per day) was 
required to be at stable doses. Patients receiving 
biologic agents or azathioprine, mercaptopurine, 
or methotrexate were required to discontinue 
these agents 5 half-lives before starting the trial 
regimen and 4 weeks before their screening en-
doscopy, respectively. A documented presence of 
varicella–zoster virus IgG antibody or complete 
varicella–zoster vaccination was required in order 
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to minimize the risk of infection. Additional 
eligibility criteria and the exclusion criteria are 
provided in the Supplementary Appendix.
Trial Design
The trial included blinded induction and mainte-
nance periods and an optional open-label period 
(Fig. S1 in the Supplementary Appendix); this 
article describes the induction and maintenance 
periods. Patients were randomly assigned, in a 
1:1:1 ratio, to receive oral ozanimod at a dose of 
0.5 mg or 1 mg (the choice of these doses was 
based on modeling of preclinical and phase 1 
data) or placebo, once daily. Patients underwent 
dose escalation during the first week after ran-
domization; thereafter, the patients received the 
randomly assigned dose for 8 weeks (see the 
Supplementary Appendix). Randomization was 
performed centrally with the use of a computer-
ized system and was stratified according to 
previous exposure to a tumor necrosis factor 
(TNF) antagonist (yes or no). Glucocorticoid 
doses were maintained unchanged through 
week 8, after which time the doses could be 
tapered at the discretion of the investigator. Pa-
tients with clinical response at week 8 continued 
their blinded regimen during the maintenance 
period. Patients who did not have a response at 
week 8 were allowed to cross over to optional 
open-label treatment.
Patients were assessed on day 1 (baseline), at 
weeks 4 and 8 (during the induction period), and 
at weeks 20 and 32 (during the maintenance 
period). Flexible sigmoidoscopy with colonic 
biopsy was performed at screening and at weeks 
8 and 32. Blinded central reading of endoscopic 
videos and histologic findings was performed. 
Adverse events and use of concomitant medica-
tions were recorded through 32 weeks. Additional 
monitoring for adverse events that were consid-
ered to be potentially relevant to S1P-receptor 
modulation is described in the Supplementary 
Appendix. Blood samples were obtained at each 
visit for clinical chemical and hematologic stud-
ies and for the measurement of the C-reactive 
protein concentration. Stool samples were ob-
tained at baseline and at weeks 8 and 32 for the 
measurement of fecal calprotectin and lactoferrin 
concentrations.
The primary outcome was clinical remission 
(Mayo Clinic score ≤2, with no subscore >1)19,20 
at week 8. The comparison of 1 mg of ozanimod 
with placebo was hierarchically ranked before 
the comparison of 0.5 mg of ozanimod with 
placebo. Hierarchically ranked secondary out-
comes at week 8 were clinical response (reduc-
tion in the Mayo Clinic score of ≥3 points and 
≥30% from baseline, with a decrease in the 
rectal-bleeding subscore of ≥1 point or a sub-
score of ≤119,20), change from baseline in the 
Mayo Clinic score, and mucosal healing (endos-
copy subscore ≤119,20). Exploratory outcomes in-
cluded clinical response, clinical remission, muco-
sal healing, and change in the Mayo Clinic score 
at week 32 and histologic remission (Geboes 
score <2, on a scale from 0 to 5, with higher 
scores indicating more severe histologic inflam-
mation)21 at weeks 8 and 32. We also examined 
changes from baseline in the absolute lympho-
cyte count and the concentrations of C-reactive 
protein, calprotectin, and lactoferrin.
Statistical Analysis
Demographic characteristics and disease charac-
teristics at baseline were compared with the use 
of descriptive statistics. Proportions of patients 
with clinical remission at week 8 were compared 
with the use of the Cochran–Mantel–Haenszel 
chi-square test, stratified according to status 
with respect to previous receipt of TNF-antago-
nist therapy. Rates of clinical remission at week 
32 and clinical response and mucosal healing at 
weeks 8 and 32 were analyzed similarly. The 
changes in the Mayo Clinic score from baseline 
to week 8 and to week 32 were analyzed with the 
use of analysis of covariance models with treat-
ment group, status with respect to previous 
TNF-antagonist therapy, and baseline value of the 
corresponding outcome included as covariates. 
Nonparametric methods were used for analysis 
of the changes from baseline in the absolute 
lymphocyte count and the concentrations of 
C-reactive protein, calprotectin, and lactoferrin.
To control for multiple comparisons, a closed 
hierarchical procedure was used for the primary 
and secondary outcomes. The order of testing 
was the primary-outcome comparison of remis-
sion rates at week 8 in the group that received 
1 mg of ozanimod with the placebo group, fol-
lowed by the comparison of remission rates at 
week 8 in the group that received 0.5 mg of 
ozanimod with the placebo group if the result 
of the primary analysis was significant (two-
sided P<0.05), followed by each major secondary 
The New England Journal of Medicine 
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outcome in order (clinical response, change in 
Mayo Clinic score from baseline, and mucosal 
healing), with comparisons for the 1-mg dose 
preceding those for the 0.5-mg dose. Analyses of 
outcomes at week 32 were prespecified as other 
secondary outcomes and were considered to be 
exploratory. The plan specified that formal test-
ing would stop if the results were not significant, 
and all subsequent analyses would be considered 
to be exploratory and the corresponding P values 
nominal.
Efficacy analyses were performed according 
to the intention-to-treat principle. For the pri-
mary analysis, as well as for the analyses of all 
secondary outcomes that were defined as pro-
portions, patients who had missing data were 
classified as not having had a response. Patients 
who did not proceed to the maintenance period 
were considered not to have had a response at 
week 32. For the secondary outcome of change 
in the Mayo Clinic score from baseline, as well as 
for the analyses of change from baseline in the 
concentrations of C-reactive protein, calprotectin, 
and lactoferrin, missing values were replaced by 
the last observation carried forward.
To compare the consistency of the effect of 
the regimen on clinical remission with placebo 
and with ozanimod at a dose of 0.5 mg or 1 mg 
once daily, we performed prespecified subgroup 
analyses (in subgroups defined according to 
previous use of TNF antagonists [yes or no], age 
[<median or ≥median], sex, colonic area involved 
[left side or extensive], and baseline Mayo Clinic 
score [≤8 or >8]). Multiple post hoc subgroup 
analyses were also performed (see the Supple-
mentary Appendix).
We anticipated that 10% of the patients in the 
placebo group would have clinical remission 
after induction therapy. We calculated that en-
rollment of 180 patients (60 patients per group) 
would provide the trial with 80% power to detect 
an absolute difference of 21 percentage points in 
the rate of clinical remission at week 8 between 
the placebo group and each ozanimod group, at 
a two-sided significance level of 0.05%.
R esult s
Characteristics of the Patients
A total of 199 patients were randomly assigned 
to the trial groups, of whom 197 received pla-
cebo or ozanimod (Fig. S2 in the Supplementary 
Appendix). One patient in the placebo group and 
one in the group assigned to receive 0.5 mg of 
ozanimod did not receive the assigned regimen 
and were excluded from the analysis. The disease 
characteristics at baseline were similar among 
the three groups (Table 1). A total of 186 of the 
197 patients (94%) completed the induction pe-
riod. At week 8, a total of 103 patients who were 
considered by the investigators to have had clini-
cal improvement (of whom 95 met the criteria 
for clinical response) continued in the blinded 
maintenance phase. Five patients who had a 
clinical response did not enter the maintenance 
phase (Table S7 in the Supplementary Appendix). 
A total of 91 of the 103 patients who entered the 
maintenance phase (88%) completed the trial.
Efficacy
Primary Outcome
At week 8, clinical remission occurred in 11 of 
67 patients (16%) who received 1 mg of ozani-
mod and in 9 of 65 patients (14%) who received 
0.5 mg of ozanimod, as compared with 4 of 65 
(6%) who received placebo (P = 0.048 and P = 0.14, 
respectively, for the comparison of the two doses 
of ozanimod with placebo) (Fig. 1A). No impor-
tant differences were observed in subgroup 
analyses that were based on demographic char-
acteristics and disease characteristics at baseline 
(Fig. S3 in the Supplementary Appendix).
Exploratory Outcomes
Given the nonsignificant findings for the com-
parison of the remission rate at week 8 in the 
group that received 0.5 mg of ozanimod with 
that in the placebo group, all subsequent analy-
ses were considered to be exploratory and the 
results not significant (nominal P values are 
provided). Clinical response at week 8 occurred 
in 24 of 65 patients (37%) in the placebo group, 
as compared with 35 of 65 (54%) who received 
0.5 mg of ozanimod (P = 0.06) and 38 of 67 
(57%) who received 1 mg of ozanimod (P = 0.02) 
(Fig. 1B). Mucosal healing at week 8 occurred in 
8 of 65 patients (12%) in the placebo group, as 
compared with 18 of 65 (28%) in the group that 
received 0.5 mg of ozanimod (P = 0.03) and 23 of 
67 (34%) in the group that received 1 mg of 
ozanimod (P = 0.002) (Fig. 1C). Histologic remis-
sion, defined as a Geboes score of less than 2, 
at week 8 occurred in 7 of 65 patients (11%) in 
the placebo group, as compared with 9 of 65 
The New England Journal of Medicine 
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(14%) in the group that received 0.5 mg of oza-
nimod (P = 0.63) and 15 of 67 (22%) in the group 
that received 1 mg of ozanimod (P = 0.07) 
(Fig. 1D).
Absolute lymphocyte counts in blood decreased 
by a mean of 32% from baseline to week 8 in 
patients who received 0.5 mg of ozanimod and 
by 49% in patients who received 1 mg of ozani-
mod. At week 8, a total of 30% of the patients 
in the group that received 0.5 mg of ozanimod 
and 53% of those in the group that received 1 mg 
of ozanimod had absolute lymphocyte counts 
Characteristic
Placebo 
(N = 65)
Ozanimod, 0.5 mg 
(N = 65)
Ozanimod, 1 mg 
(N = 67)
Male sex — no. (%) 35 (54) 32 (49) 48 (72)
Age — yr 41.9±12.3 38.8±12.1 41.8±11.0
White race — no. (%)† 61 (94) 59 (91) 62 (93)
Body weight — kg 72.6±14.9 72.3±16.9 77.4±16.3
Current smoker — no. (%) 3 (5) 4 (6) 4 (6)
Age at diagnosis — yr 35.8±13.0 33.1 ±11.3 35.2±12.1
Time since diagnosis — yr 6.1±5.5 5.9±5.4 6.7±6.8
Mayo Clinic score‡ 8.6 ±1.5 8.3±1.5 8.5±1.6
Partial Mayo Clinic score‡ 6.1±1.3 5.8±1.3 6.0±1.3
C-reactive protein — mg/liter
Median 4.9 3.9 4.3
Range 0.20–141.4 0.10–131.2 0.10–82.5
Fecal calprotectin — μg/g
Median 1272 1477 1238
Range 30–8380 66–11,108 10–10,511
Lactoferrin — μg/g
Median 29.0 30.6 29.9
Range 1.4–1049 1.4–483 1.4–586
Hemoglobin — g/liter 123.7±20.1 119.7±20.5 126.0±20.7
Extent of disease — no. (%)
Left side of colon 41 (63) 41 (63) 41 (61)
Extensive 24 (37) 24 (37) 26 (39)
Concomitant medication use — no. (%)
Glucocorticoid 24 (37) 22 (34) 27 (40)
Aminosalicylate 57 (88) 53 (82) 53 (79)
Previous medication use — no. (%)
Immunosuppressive agent§ 17 (26) 24 (37) 22 (33)
TNF-antagonist therapy 10 (15) 13 (20) 13 (19)
*  Plus–minus values are means ±SD. There were no significant differences among the three groups in any of the base-
line characteristics. Normal values are as follows: C-reactive protein, less than 5 mg per liter; fecal calprotectin, less 
than 50 μg per gram of stool; lactoferrin, 6.0 μg or less per gram of stool; and hemoglobin, 125 to 170 g per liter in 
men and 110 to 155 g per liter in women. TNF denotes tumor necrosis factor.
†  Race was self-reported.
‡  The Mayo Clinic score was used to measure disease activity; scores range from 0 to 12, with higher values indicating 
more severe disease. The partial Mayo Clinic score consists of the Mayo Clinic score minus the sigmoidoscopy sub-
score; the partial score ranges from 0 to 9, with higher scores indicating more active disease.
§  Immunosuppressive agents included azathioprine, methotrexate, and mercaptopurine.
Table 1. Demographic Characteristics and Disease Characteristics at Baseline, According to Trial Group.*
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that were below the lower limit of the normal 
range, with the majority of patients in each oza-
nimod group having grade 1 or grade 2 reduc-
tions in the lymphocyte count. A total of 9 of 67 
patients in the group that received 1 mg of 
ozanimod had grade 3 reductions in the lym-
phocyte count, and no patient in either ozani-
mod group had grade 4 lymphopenia (Table S6 
in the Supplementary Appendix).
Figure 2 shows the proportions of patients 
with clinical remission, clinical response, muco-
sal healing, and histologic remission at week 32. 
A total of 2 of 4 patients with remission at week 
8 in the placebo group, 7 of 9 in the group that 
received 0.5 mg of ozanimod, and 5 of 11 in the 
group that received 1 mg of ozanimod still had 
remission at week 32. Reductions in the Mayo 
Clinic score and in the serum and fecal inflam-
matory laboratory variables (C-reactive protein, 
calprotectin, and lactoferrin concentrations) were 
consistent with the higher degree of efficacy 
seen in the group that received 1 mg of ozani-
mod (Table S12 in the Supplementary Appen-
dix). These data should be interpreted cautiously 
given that the usefulness of these markers is 
highly dependent on clinical context.22
Figure 1. Efficacy Outcomes at Week 8 in the Trial of Ozanimod as Induction Therapy.
Panel A shows the percentage of patients in the three trial groups who had a clinical remission (Mayo Clinic score 
≤2, with no individual subscore >1) at week 8 (the primary outcome). Mayo Clinic scores range from 0 to 12, with 
higher values indicating more severe disease; subscores range from 0 to 3, with higher scores indicating more se-
vere disease. Panel B shows the percentage of patients who had a clinical response (defined as a reduction from 
baseline in the Mayo Clinic score of ≥3 points and ≥30%, and a decrease from baseline in the rectal-bleeding sub-
score of ≥1 point or an absolute rectal-bleeding subscore of ≤1 point) at week 8. Panel C shows the percentage of 
patients with mucosal healing (endoscopy subscore of ≤1 point) at week 8. Panel D shows the percentage of patients 
with histologic remission (Geboes score <2, on a scale from 0 to 5, with higher scores indicating more severe histo-
logic inflammation) at week 8. P values reported for analyses other than the primary outcome of clinical remission 
at week 8 are considered to be nominal and not significant.
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Safety
No important differences were observed among 
the groups in the most commonly reported ad-
verse events during the trial (Table 2). One pa-
tient in the 0.5-mg ozanimod group who had 
evidence of preexisting bradycardia (heart rate of 
50 beats per minute and a PR interval of 198 msec 
before ozanimod treatment was initiated) had 
first-degree atrioventricular block and sinus 
bradycardia on day 8 (heart rate, 46 beats per 
minute; PR interval, 201 msec [upper limit of the 
normal range, 200 msec]); this event was asymp-
tomatic and transient and resolved without inter-
vention. The patient discontinued treatment after 
these events. Four patients who received ozani-
mod (one patient who received 0.5 mg and three 
who received 1 mg) had an increase in the ala-
nine aminotransferase level of more than 3 times 
the upper limit of the normal range during treat-
ment. Squamous-cell carcinoma of the skin de-
veloped in one patient who received 1 mg of 
ozanimod; this patient had previously been treat-
ed with mercaptopurine for more than 2 years.
Discussion
In this phase 2 trial involving patients with 
moderately or severely active ulcerative colitis, 
treatment with ozanimod at a once-daily oral 
dose of 1 mg resulted in slightly higher rates of 
clinical remission at week 8 than those with 
placebo (16% vs. 6%, P = 0.048). At week 32, pa-
tients receiving 1 mg of ozanimod continued to 
have higher rates of clinical remission, clinical 
response, mucosal healing, and histologic re-
mission, as well as lower Mayo Clinic scores, 
than those with placebo. The increases in the 
proportions of patients with clinical remission 
and with histologic remission at week 32, as 
compared with week 8, raise the possibility that 
Figure 2. Exploratory Efficacy Outcomes at Week 32 in the Trial of Ozanimod as Maintenance Therapy.
The P values reported for these analyses are considered to be nominal and not significant.
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extended treatment may be associated with en-
hanced efficacy.
Studies of other agents, notably monoclonal 
antibodies directed toward adhesion molecules, 
have previously shown that interference with 
lymphocyte trafficking is an effective therapeu-
tic approach for patients with ulcerative colitis. 
The use of orally administered small molecules 
as alternatives to injectable monoclonal antibod-
ies for the treatment of ulcerative colitis has both 
advantages and disadvantages. With respect to 
the advantages, the convenience of oral admin-
istration is attractive to patients and providers. 
Even more important, avoidance of sensitization 
with the formation of antidrug antibodies has 
the potential to eliminate one of the most im-
portant reasons for the failure of treatment with 
monoclonal antibodies. Alternatively, small mol-
ecules can be less selective than monoclonal 
antibodies, and off-target binding may result in 
adverse effects.
This trial was not large enough or of suffi-
ciently long duration to assess the safety of 
ozanimod. As noted previously, S1P-receptor 
Event
Placebo 
(N = 65)
Ozanimod, 0.5 mg 
(N = 65)
Ozanimod, 1 mg 
(N = 67)
No. of adverse events 59 45 51
Adverse event — no. of patients (%) 26 (40) 26 (40) 26 (39)
Serious adverse event — no. of patients (%)* 6 (9) 1 (2) 3 (4)
Adverse event leading to discontinuation of regimen 
— no. of patients (%)
4 (6) 3 (5) 1 (1)
Adverse cardiac event — no. of patients (%) 2 (3) 1 (2) 0
Adverse event occurring in ≥2 patients receiving 
ozanimod — no. of patients (%)
Ulcerative colitis flare 5 (8) 2 (3) 3 (4)
Anemia 4 (6) 3 (5) 0
Headache 3 (5) 0 2 (3)
Nausea 2 (3) 1 (2) 2 (3)
Pyrexia 0 1 (2) 3 (4)
Arthralgia 1 (2) 1 (2) 2 (3)
Alanine aminotransferase increased 0 1 (2) 3 (4)
Back pain 1 (2) 1 (2) 1 (1)
Rash 0 1 (2) 2 (3)
Abdominal pain 1 (2) 1 (2) 1 (1)
Vomiting 0 0 2 (3)
Orthostatic hypotension 0 2 (3) 0
Aspartate aminotransferase increased 0 1 (2) 1 (1)
Hyperbilirubinemia 0 1 (2) 1 (1)
Insomnia 0 1 (2) 1 (1)
Nasopharyngitis 0 2 (3) 0
Proctalgia 0 1 (2) 1 (1)
*  A serious adverse event was defined as any untoward medical occurrence that resulted in death, was life-threatening 
(was associated with an immediate risk of death), required admission to a hospital or prolongation of existing hospital-
ization, resulted in persistent or clinically significant disability or incapacity, or resulted in a congenital anomaly or birth 
defect. Events occurring in the placebo group included worsening ulcerative colitis in three patients, iron-deficiency 
anemia in one, herpes zoster infection and autoimmune hemolytic anemia in one, and jaundice in one. One patient in 
the group that received 0.5 mg of ozanimod had hyperpyrexia. Events occurring in the group that received 1.0 mg of 
ozanimod included worsening ulcerative colitis in two patients and adenoma of the colon in one.
Table 2. Safety Findings in Induction and Maintenance Phases, According to Trial Group.
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modulators have been associated with cardiac and 
hepatic effects.15 Elevations in hepatic amino-
transferase levels were observed in four patients 
(3%) receiving ozanimod and require further 
evaluation. First-degree atrioventricular block 
and sinus bradycardia developed on day 8 in one 
patient who was treated with ozanimod. Patients 
with clinically significant cardiovascular dis-
ease, including those with bradycardia and those 
taking medications that affect the cardiac con-
duction system, were excluded from the trial, so 
our findings cannot be extrapolated to these 
patient populations.
Our trial had some limitations. First, the time 
point of week 8 that was chosen for the evalua-
tion of efficacy during induction may not be 
long enough for drugs that target lymphocyte 
trafficking, a possibility that is supported by the 
enhanced benefits seen in maintenance with 
antitrafficking agents.2 Second, as noted above, 
given the relatively brief duration of observation 
and the small number of patients evaluated, we 
cannot assess the safety of ozanimod. Third, 
ozanimod treatment resulted in large reductions 
from baseline in absolute lymphocyte counts, 
with most patients in the group that received 1 mg 
having counts below the lower limit of the nor-
mal range at week 8 — a finding that is consis-
tent with the mechanism of the drug. Future 
studies are needed to assess the risk of infec-
tions associated with ozanimod. Finally, the 
trial was limited to patients receiving ozanimod 
as monotherapy or in combination with gluco-
corticoids or aminosalicylates.
In conclusion, in this preliminary trial, oza-
nimod at a dose of 1 mg was associated with a 
slightly higher rate of clinical remission among 
patients with moderately to severely active ulcer-
ative colitis than the rate with placebo. Efficacy 
requires further assessment in larger trials. This 
trial was not large enough or of sufficiently long 
duration to assess safety.
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